Eichenfield Lawrence 4

What Happened
Lawrence Eichenfield, a director of Verrica Pharmaceuticals (VRCA), received a grant covering 16,000 shares reported as a derivative award on June 5, 2026. The award shows an acquisition price of $0.00 (no cash exchanged) and is recorded as an award/grant rather than a purchase or sale.

Key Details

• Transaction date: 2026-06-05; reported on Form 4 filed 2026-06-09.
• Instrument/pricing: Award of 16,000 shares at $0.00 (derivative grant).
• Shares owned after transaction: Not specified in the summary filing.
• Footnote: The underlying shares vest and become exercisable in 12 equal monthly installments beginning July 5, 2026, and will be fully vested by the next annual meeting of stockholders, subject to continued service as a director.
• No indication this was an exercise, sale, or cash transaction — it is a compensation grant.

Context
This is a typical director compensation grant (not an open-market purchase or sale). The award vests over time and does not represent immediate saleable stock until vested/exercised per the vesting schedule. Such grants are common for non-employee directors and reflect compensation rather than a direct market signal.